Back to Search
Start Over
Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID‐19
- Source :
- Clinical and Translational Science, Vol 13, Iss 5, Pp 880-885 (2020), Clinical and Translational Science
- Publication Year :
- 2020
- Publisher :
- Wiley, 2020.
-
Abstract
- Since December 2019, a novel coronavirus (severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2)) infection has been rapidly spreading worldwide and causing the respiratory illness, coronavirus disease 2019 (COVID-19). The antiretroviral drug favipiravir (FPV) has been experimentally used for COVID-19 treatment since March 2020 in Japan. However, the pharmacokinetics of FPV in critically ill patients is unknown. We measured the serum concentration of FPV using high-performance liquid chromatography in patients with severe COVID-19 who were admitted to the intensive care unit and placed on mechanical ventilation. The patients were administered 1,600 mg of FPV twice daily on day 1, followed by 600 mg twice daily from day 2 to day 5 (or more if needed). Suspensions of FPV tablets were administered through a nasogastric tube. Seven patients were enrolled in this study. Forty-nine blood samples were obtained from the eligible patients to evaluate FPV concentration. The FPV trough (after 8-12 hours) concentrations of most samples were lower than the lower limit of quantification (1 µg/mL) and half-maximal effective concentration (9.7 µg/mL) against SARS-CoV-2 previously tested in vitro. FPV trough concentration in critically ill patients was much lower than that of healthy subjects in a previous clinical trial, which is a cause for great concern. Further study is required to determine the optimal strategy for treatment of patients with severe COVID-19.
- Subjects :
- Male
030213 general clinical medicine
medicine.medical_treatment
medicine.disease_cause
Severity of Illness Index
030226 pharmacology & pharmacy
SARS‐CoV‐2
law.invention
0302 clinical medicine
law
General Pharmacology, Toxicology and Pharmaceutics
Intubation, Gastrointestinal
Coronavirus
Brief Report
General Neuroscience
lcsh:Public aspects of medicine
General Medicine
Intensive care unit
Treatment Outcome
Pyrazines
Female
Coronavirus Infections
Tablets
Adult
medicine.medical_specialty
Critical Illness
Pneumonia, Viral
Favipiravir
Drug Administration Schedule
General Biochemistry, Genetics and Molecular Biology
Betacoronavirus
03 medical and health sciences
Suspensions
Pharmacokinetics
COVID‐19
Internal medicine
Severity of illness
medicine
Humans
Trough Concentration
Pandemics
Aged
Mechanical ventilation
Dose-Response Relationship, Drug
SARS-CoV-2
business.industry
lcsh:RM1-950
COVID-19
lcsh:RA1-1270
medicine.disease
Amides
Respiration, Artificial
COVID-19 Drug Treatment
Pneumonia
lcsh:Therapeutics. Pharmacology
Brief Reports
business
Subjects
Details
- Language :
- English
- ISSN :
- 17528054 and 17528062
- Volume :
- 13
- Issue :
- 5
- Database :
- OpenAIRE
- Journal :
- Clinical and Translational Science
- Accession number :
- edsair.doi.dedup.....bb2f8f8997cf5cece50d8e5fd4678b57